FDA approves Parkinson's drug with novel dopamine receptor mechanism

The US approved a new Parkinson's disease treatment that acts on different dopamine receptors than existing drugs in its class, offering a potential alternative for patients with suboptimal response. The approval is based on clinical data, but long-term comparative efficacy and safety versus standard therapies remain uncertain. This expands the therapeutic arsenal for a progressive neurological condition.